Orris

New updates on hyponatremia

Reading File
Reading File
Finding Sources
Searching PubMed

hyponatremia AND management

Searching the Web

hyponatremia treatment guideline update 2025 2026

Reading Article

PMID: 41114681

Reading Article

PMID: 39556338

Reading Article

PMID: 39362395

Reading Web Page

https://www.hcplive.com/view/new-european-hyponatremia-guide…

New Updates on Hyponatremia

Here's a synthesis of the most clinically relevant developments from the last 1-2 years, drawn from recent systematic reviews, meta-analyses, and new society guidance.

1. Faster correction may be safer than previously assumed

A 2025 systematic review and meta-analysis in JAMA Internal Medicine (16 cohort studies, ~11,800 hospitalized patients with severe hyponatremia) found that rapid correction (≥8-10 mEq/L per 24h) was associated with fewer in-hospital and 30-day deaths than slow or very slow correction, without a statistically significant increase in osmotic demyelination syndrome (ODS) risk. This challenges the traditionally conservative correction limits and suggests overly cautious correction may itself carry mortality risk (Ayus et al., JAMA Intern Med, 2025 - PMID: 39556338).
  • This is an important nuance for practice: current guideline limits (typically ≤8-10 mEq/L/24h, ≤18 mEq/L/48h) remain the standard to avoid ODS, but this data pushes back against "very slow" correction strategies in symptomatic severe hyponatremia.

2. New European hyponatremia guidelines (ESICM/ESE/ERA-EDTA)

A joint update from the European Society of Intensive Care Medicine, European Society of Endocrinology, and European Renal Association clarifies the diagnostic and treatment approach in adults (serum Na <135 mmol/L):
  • Severe/symptomatic hyponatremia (acute or chronic): prompt infusion of 3% hypertonic saline with close sodium monitoring in the first 24 hours.
  • Moderately severe symptoms: hypertonic saline targeting a ~5 mmol/L rise per 24h, capping the increase at 10 mmol/L in the first 24h and 8 mmol/L per 24h thereafter.
  • Syndrome of Inappropriate Antidiuresis (SIAD): fluid restriction remains first-line for moderate/profound hyponatremia; second-line options are increased solute intake via oral urea (0.25-0.50 g/kg/day) or low-dose loop diuretic plus oral sodium chloride.
  • The guidelines recommend against lithium, demeclocycline, and vasopressin receptor antagonists (vaptans) for moderate SIAD-related hyponatremia.
  • Pediatric hyponatremia is explicitly excluded as a distinct area needing separate guidance.

3. Urea re-emerges as an evidence-supported option for SIAD

A 2025 systematic review/meta-analysis in the American Journal of Kidney Diseases found oral urea significantly raised serum sodium in SIAD-related hyponatremia (mean difference ~9 mEq/L), was comparable in efficacy to both fluid restriction and vaptans, and was superior to no treatment, with minor adverse effects (poor palatability being the main limitation). No RCTs exist yet, so evidence is based on observational data, but this supports urea as a practical, low-cost option, especially in resource-limited settings (Chander et al., 2025 - PMID: 39362395).

4. AGA Clinical Practice Update on hyponatremia in cirrhosis (2025)

The American Gastroenterological Association issued a focused expert review on managing hyponatremia alongside ascites/volume overload in cirrhosis:
  • Outpatient management of asymptomatic hypervolemic hyponatremia: sodium and fluid restriction (1-1.5 L/day), diuretic/laxative adjustment, electrolyte monitoring.
  • Inpatient severe/symptomatic disease: fluid/sodium restriction, diuretic/laxative discontinuation, IV albumin based on volume status, or oral vasoconstrictor therapy.
  • Recurrent/refractory cases warrant a multidisciplinary approach including liver transplant evaluation, since hyponatremia independently worsens post-transplant outcomes (Orman et al., Gastroenterology, 2025 - PMID: 41114681).

5. Other notable findings

  • Hypertonic saline delivery method: a 2025 systematic review/meta-analysis found no major safety difference between rapid intermittent bolus vs. slow continuous infusion of 3% saline for symptomatic severe hyponatremia (PMID: 40053429), supporting bolus dosing as a reasonable, more practical option in many settings.
  • Hyponatremia continues to be identified as a strong prognostic marker in specific populations: post-subarachnoid hemorrhage (associated with vasospasm and longer stay), traumatic brain injury (worse GCS/prognosis), and post-transsphenoidal pituitary surgery (common, delayed-onset complication needing extended monitoring).

Bottom line

The main paradigm shift is around correction rate for severe hyponatremia - the balance of evidence now leans toward avoiding under-correction as much as overly rapid correction, given the mortality signal, while ODS-limiting caps in the new European guidelines are still recommended as the practical ceiling. Urea is gaining traction as a viable alternative/adjunct to fluid restriction and vaptans for SIAD, particularly with these new guidelines explicitly endorsing it as second-line therapy.
I did not find anything indicating a new FDA drug approval specific to hyponatremia in this window - the changes are primarily in management strategy and correction-rate evidence rather than new pharmacotherapy.
This is a shared conversation. Sign in to Orris to start your own chat.